As of November 7, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Perspective Therapeutics, Inc. The largest reported stake is Commodore Capital LP's, at 9.9%. 16 filings are on record since November 7, 2025 (Schedule 13G, February 9, 2026).
Sell to companies like Perspective Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Lantheus Holdings, Inc. · Sole voting: 0 · Shared voting: 8,739,011 · Sole dispositive: 0 · Shared dispositive: 8,739,011 · SCHEDULE 13D/A, 2026-09-23
- · Holder: Lantheus Holdings, Inc. · Percent: 10% · SCHEDULE 13D/A
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 5,888,184 · Sole dispositive: 0 · Shared dispositive: 5,888,184 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 5,942,306 · Sole dispositive: 0 · Shared dispositive: 6,051,771 · SCHEDULE 13G, 2026-08-07
- · Reporting person: BlackRock, Inc. · Sole voting: 7,679,840 · Shared voting: 0 · Sole dispositive: 7,776,940 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29
Perspective Therapeutics, Inc. has 16 Schedule 13D or 13G filings on record since 2025-11-07. 8 holders' latest filing reports 5% or more of common stock, $0.001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Commodore Capital LP | 9.9% | 11,939,753 | SCHEDULE 13G, 2026-02-09 | 2026-02-02 |
| Lantheus Holdings, Inc. | 7.7% | 8,739,011 | SCHEDULE 13D/A, 2026-09-23 | 2026-09-21 |
| 6.9% | 7,915,567 | SCHEDULE 13G, 2026-02-06 | 2026-02-03 | |
| BlackRock, Inc. | 6.8% | 7,776,940 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| Qatar Investment Authority | 6.2% | 7,073,308 | SCHEDULE 13G, 2026-02-05 | 2026-02-04 |
| Millennium Management LLC | 5.5% | 6,316,545 | SCHEDULE 13G/A, 2026-08-13 | 2026-08-07 |
| Avidity Partners Management LP | 5.3% | 6,049,999 | SCHEDULE 13G, 2026-03-10 | 2026-02-20 |
| State Street Corporation | 5.3% | 6,051,771 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| 2.6% | 2,959,296 | SCHEDULE 13G/A, 2026-05-12 | 2026-03-31 | |
| Fmr LLC | 0.4% | 312,164 | SCHEDULE 13G/A, 2025-12-05 | 2025-11-28 |
Holding shares or following this stake? See who's behind Perspective Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Perspective Therapeutics, Inc. and the records around it.
Perspective Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Lantheus Holdings, Inc. also filed stake reports on 1 other company: Radiopharm Theranostics Limited (Sep 2026)
- Avidity Partners Management LP also filed stake reports on 5 other companies: Context Therapeutics Inc. (May 2026), Immunic, Inc. (Apr 2026), Scynexis, Inc. (Feb 2026)
- Qatar Investment Authority also filed stake reports on 11 other companies: Aspen Neuroscience, Inc. (Nov 2026), Global Business Travel Group, Inc. (Sep 2026), Nanobiotix SA (Jul 2026)
Watch Perspective Therapeutics, Inc.
Get an email when Perspective Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Perspective Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Perspective Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Perspective Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Lantheus Holdings, Inc. | 0 | 8,739,011 | 0 | 8,739,011 | SCHEDULE 13D/A, 2026-09-23 |
| Lantheus Medical Imaging, Inc. | 0 | 8,739,011 | 0 | 8,739,011 | SCHEDULE 13D/A, 2026-09-23 |
| Lantheus Alpha Therapy, LLC | 0 | 8,739,011 | 0 | 8,739,011 | SCHEDULE 13D/A, 2026-09-23 |
| BlackRock, Inc. | 7,679,840 | 0 | 7,776,940 | 0 | SCHEDULE 13G, 2026-07-29 |
| Integrated Core Strategies (US) LLC | 0 | 5,888,184 | 0 | 5,888,184 | SCHEDULE 13G/A, 2026-08-13 |
| Millennium Management LLC | 0 | 6,316,545 | 0 | 6,316,545 | SCHEDULE 13G/A, 2026-08-13 |
| Millennium Group Management LLC | 0 | 6,316,545 | 0 | 6,316,545 | SCHEDULE 13G/A, 2026-08-13 |
| Israel A. Englander | 0 | 6,316,545 | 0 | 6,316,545 | SCHEDULE 13G/A, 2026-08-13 |
| State Street Corporation | 0 | 5,942,306 | 0 | 6,051,771 | SCHEDULE 13G, 2026-08-07 |
The latest filing identifies Perspective Therapeutics, Inc. by CUSIP 46489V302 and gives its principal executive office as 2401 Elliott Avenue, Suite 320, Seattle, WA 98121 (SCHEDULE 13D/A, 2026-09-23).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-07 | Fmr LLC | 8.2% | SCHEDULE 13G/A |
| 2025-12-05 | Fmr LLC | 0.4% | SCHEDULE 13G/A |
| 2026-02-05 | Qatar Investment Authority | 6.2% | SCHEDULE 13G |
| 2026-02-06 | Chen Yu | 6.9% | SCHEDULE 13G |
| 2026-02-09 | Commodore Capital LP | 9.9% | SCHEDULE 13G |
| 2026-02-12 | Morgan Stanley | 6% | SCHEDULE 13G |
| 2026-03-10 | Avidity Partners Management LP | 5.3% | SCHEDULE 13G |
| 2026-04-27 | BlackRock, Inc. | 4.6% | SCHEDULE 13G/A |
| 2026-05-12 | Morgan Stanley | 2.6% | SCHEDULE 13G/A |
| 2026-06-30 | Millennium Management LLC | 4.3% | SCHEDULE 13G |
| 2026-07-20 | Millennium Management LLC | 5.3% | SCHEDULE 13G |
| 2026-07-29 | BlackRock, Inc. | 6.8% | SCHEDULE 13G |
| 2026-08-07 | State Street Corporation | 5.3% | SCHEDULE 13G |
| 2026-08-13 | Millennium Management LLC | 5.5% | SCHEDULE 13G/A |
| 2026-09-04 | Lantheus Holdings, Inc. | 10% | SCHEDULE 13D/A |
| 2026-09-23 | Lantheus Holdings, Inc. | 7.7% | SCHEDULE 13D/A |
Questions about who owns Perspective Therapeutics, Inc.
Who owns Perspective Therapeutics, Inc.?
On this page, 8 holders' latest ownership filings report 5% or more of Perspective Therapeutics, Inc.: Commodore Capital LP (9.9%, Schedule 13G, filed 2026-02-09), Lantheus Holdings, Inc. (7.7%, Schedule 13D/A, filed 2026-09-23), Chen Yu (6.9%, Schedule 13G, filed 2026-02-06), BlackRock, Inc. (6.8%, Schedule 13G, filed 2026-07-29) and Qatar Investment Authority (6.2%, Schedule 13G, filed 2026-02-05); 3 more are listed above.
Who are the largest shareholders of Perspective Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Perspective Therapeutics, Inc. on this page are Commodore Capital LP (9.9%), Lantheus Holdings, Inc. (7.7%) and Chen Yu (6.9%).
When did Commodore Capital LP buy into Perspective Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Commodore Capital LP on this page is the Schedule 13G, filed 2026-02-09, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Perspective Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.